Skip to content

Depression: all studies

Page 802 of 1,034: studies 8,011 to 8,020 of 10,336, newest first. Back to the depression overview

Research

Prevalence and Detailed Experience of Nightmare and Nightmare Disorder in Chinese University Students

Sage Open April 1, 2021 Chu Wang, Jiayao Xu, Mufan Wang et al. 7 citations

Nightmares influence the mental health of university students, but the prevalence of nightmare and nightmare disorder requires additional documentation. The data of detailed nightmare experience of nightmare disorder and related depressive mood in this population are also scarce. First, a total of 1,451 students in a comprehensive Chinese university were invited to report their nightmare...

DOI: 10.1177/21582440211014193 (opens in new tab) Nightmare Population Mental health Clinical psychology

I-mindfulness-based cognitive therapy (i-MBCT) in the treatment of COVID-19 related adjustment disorder. a RCT study with active control group

European Psychiatry April 1, 2021 Paweł Holas

Introduction Adjustment disorder (AD) is described as a maladaptive reaction to an identifiable psychosocial stressor/s that usually emerges within a month after the onset of the stressor. With all uncertainty, fears and disorientation, it’s no surprise that many people have developed an AD linked to the sudden changes brought about by COVID-19, such as threat to life, imposed restrictions, and...

Loving-Kindness Meditation vs Cognitive Processing Therapy for Posttraumatic Stress Disorder Among Veterans

JAMA Network Open April 1, 2021 David J. Kearney, Carol A. Malte, Meghan Storms et al.

Key Points Question Is group loving-kindness meditation noninferior to group cognitive processing therapy for treatment of posttraumatic stress disorder (PTSD) among veterans? Findings In this randomized clinical trial, 184 veterans with PTSD were assigned to group loving-kindness meditation or group cognitive processing therapy; the differences in the decrease from baseline to 6-month...

Efficacy and safety results from the first pivotal phase 3 randomized controlled trial of mdma-assisted psychotherapy for treatment of severe chronic PTSD

European Psychiatry April 1, 2021 B. Van der Kolk

Introduction Posttraumatic stress disorder is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment options. Previous research has led to the designation of 3,4-methylenedioxymethamphetamine (MDMA) as a Breakthrough Therapy for treatment of post-traumatic stress disorder (PTSD) when administered as an adjunct to psychotherapy....

Ayahuasca potential benefits

European Psychiatry April 1, 2021 R. Pinilla, Carmen Rocamora Rodriguez, D. Batet-Sanchez et al. 3 citations

Introduction Ayahusca has potential therapeutic beneffits. Objectives Expose the potential beneffits of ayahuasca from neuropharmacology and clinical existing evidence. Methods A literature review was carried out in the databases pubmed, clinical key and texts of scientific dissemination. Results There´s scientific literature about the potential therapeutic use of ayahuasca in dependencies,...

Psychedelics and psychiatric disorders: A emerging role

European Psychiatry April 1, 2021 Clayton Peixoto, Fabiano Santos, Daianne Cardinalli Rêgo et al. 1 citation

Introduction Recently there has been renewal in interest of psychedelic research. Classic psychedelics such as lysergic acid diethylamide (LSD), psilocybin and mescaline act pharmacologically as agonists at the 5-HT2A receptor. The entactogens like methylenedioxymethamphetamine (MDMA), acts as a serotonin, dopamine and noradrenaline agonist. All of these drugs are potential candidates in the...

Psychedelics: A new era of treatment?

European Psychiatry April 1, 2021 S. Torres 2 citations

Introduction Psychedelics - including LSD (lysergic acid diethylamide), psilocybin, DMT (N, N-dimethyltryptamine), ayahuasca and mescaline - have an ancient history across various civilizations. In 1950, after LSD’s discovery by Hofmann, psychedelics enjoyed a short-lived relationship with psychiatry, before prohibitive legislature emerging in response to the recreational use in the mid-1960s....

Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far?

European Psychiatry April 1, 2021 Nelson Descalço, Ana Beatriz Medeiros, Cátia Fernandes Santos et al. 1 citation

Introduction Psilocybin is a naturally occurring plant alkaloid in mushrooms and a prodrug of psilocin. It is a serotonin receptor (5-HT2A) agonist and known psychedelic, with similar hallucinatory properties to lysergic acid diethylamide (LSD). It has been identified as a safe and effective option in treatment-resistant depression. Literature focus mainly on its use on depressive but its...

Sleep, dreams, nightmares, and sex-related differences: a narrative review.

European review for medical and pharmacological sciences April 1, 2021 R Cappadona, A De Giorgi, E Di Simone et al. 7 citations

The aim of this study was to review the available findings on sex-related differences for sleep disorders, dreams and nightmares. We explored the PubMed, EMBASE and Google Scholar electronic databases, with regards to the searching terms 'sleep', 'dreams', and 'nightmares' associated with 'sex' and/or 'gender'. Moreover, other supplementary terms for the searching strategy were 'chronobiology',...

Mindfulness-based stress reduction for medical students: a narrative review

Canadian Medical Education Journal March 31, 2021 E. Polle, J. Gair

Background Medical students are at high risk of depression, distress and burnout, which may adversely affect patient safety. There has been growing interest in mindfulness in medical education to improve medical student well-being. Mindfulness-based stress reduction (MBSR) is a commonly used, standardized format for teaching mindfulness skills. Previous research has suggested that MBSR may be...